Tessa Therapeutics Pte Ltd., of Singapore, appointed Jennifer Butler chief commercial officer. She will be responsible for driving the global launch and commercialization strategy of Tessa’s advanced T-cell therapy pipeline, including the company’s lead product, TT10, which is currently in a global Phase III trial for the treatment of nasopharyngeal carcinoma. Butler will be based in the U.S. and will be leading the expansion of the company’s U.S. business operations.